Soleno Therapeutics (SLNO) Now Covered By Roth Capital with $14.0000 Target; Pro Dex (PDEX) Has 3 Sentiment

Pro-Dex, Inc. (NASDAQ:PDEX) Logo

Pro Dex Inc (PDEX) investors sentiment increased to 3 in 2018 Q1. It’s up 1.50, from 1.5 in 2017Q4. The ratio is better, as 6 investment managers increased or started new positions, while 2 decreased and sold stakes in Pro Dex Inc. The investment managers in our database now possess: 270,873 shares, up from 256,735 shares in 2017Q4. Also, the number of investment managers holding Pro Dex Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 0 Reduced: 2 Increased: 4 New Position: 2.

In a a research note revealed on Friday morning, Roth Capital analyst just began coverage of Soleno Therapeutics Inc (SLNO) with “Buy” rating. The TP is set to $14.0000.

Pro-Dex, Inc., together with its subsidiaries, designs, develops, and makes powered surgical instruments for medical device original equipment manufacturers, dental instruments, and rotary air motors worldwide. The company has market cap of $28.73 million. It also makes plastic injection molds for various industries; and machined parts. It has a 12.84 P/E ratio. Further, it provides engineering consulting and placement services, as well as quality and regulatory consulting services.

Since January 1, 0001, it had 1 buy, and 1 sale for $5,085 activity.

Thompson Davis & Co. Inc. holds 0.04% of its portfolio in Pro-Dex, Inc. for 2,000 shares. First Wilshire Securities Management Inc owns 14,000 shares or 0.03% of their US portfolio. Moreover, Bridgeway Capital Management Inc has 0.01% invested in the company for 76,600 shares. The Massachusetts-based Acadian Asset Management Llc has invested 0% in the stock. Blackrock Inc., a New York-based fund reported 655 shares.

It closed at $6.6 lastly. It is down 15.68% since June 24, 2017 and is uptrending. It has outperformed by 3.11% the S&P500. Some Historical PDEX News: 10/05/2018 – PRO-DEX INC QTRLY NET SALES DOWN 17 PCT TO $5.5 MLN; QTRLY SHR $0.11; 19/04/2018 DJ Pro-Dex Inc, Inst Holders, 1Q 2018 (PDEX)

More important recent Soleno Therapeutics, Inc. (NASDAQ:SLNO) news were published by: which released: “Roth Capital Starts Soleno Therapeutics Inc. (SLNO) at Buy” on June 22, 2018, also published article titled: “40 Stocks Moving In Friday’s Mid-Day Session”, published: “Benzinga’s Top Upgrades, Downgrades For June 22, 2018” on June 22, 2018. More interesting news about Soleno Therapeutics, Inc. (NASDAQ:SLNO) was released by: and their article: “Soleno Therapeutics To Present Corporate Update at the BIO International Convention” with publication date: June 04, 2018.

The stock increased 33.05% or $0.77 during the last trading session, reaching $3.1. About 9.71 million shares traded or 5107.22% up from the average. Soleno Therapeutics, Inc. (SLNO) has declined 41.31% since June 24, 2017 and is downtrending. It has underperformed by 53.88% the S&P500. Some Historical SLNO News: 16/05/2018 – SOLENO THERAPEUTICS SAYS QTRLY SHR LOSS FROM CONT OPS $0.17 – SEC FILING; 14/05/2018 Soleno Therapeutics Announces Initiation of Phase lll Clinical Trial of DCCR in Prader-Willi Syndrome; 14/05/2018 – Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome; 14/05/2018 – SOLENO THERAPEUTICS INC – TRIAL IS ANTICIPATED TO TAKE APPROXIMATELY 9-12 MONTHS TO COMPLETE

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company has market cap of $61.28 million. The company's lead candidate, diazoxide choline controlled-release , a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development. It currently has negative earnings. It also markets medical devices, including the CoSense End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns; and NeoPip T-piece resuscitator and related consumables, which deliver consistent pre-set inspiratory pressure and positive end-expiratory pressures, as well as temperature probes, scales, surgical tables, and patient surfaces.

Among 3 analysts covering Soleno Therapeutics Inc (SLNO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Soleno Therapeutics Inc has $14 highest and $400 lowest target. $7.67’s average target is 147.42% above currents $3.1 stock price. Soleno Therapeutics Inc had 4 analyst reports since July 5, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, July 5 by Maxim Group. The stock has “Buy” rating by Maxim Group on Monday, August 14.

Pro-Dex, Inc. (NASDAQ:PDEX) Institutional Positions Chart